HIF-1α 	HIF-1α 	 FW	B-NP
/ 	/ 	 FW	O
MDR1  	MDR1  	 FW	B-NP
pathway  	pathway  	 FW	I-NP
confers  	confers  	 FW	O
chemoresistance  	chemoresistance  	 FW	B-NP
to  	to  	 TO	O
cisplatin  	cisplatin  	 VB	O
in  	in  	 IN	O
bladder  	bladder  	 JJ	O
cancer  	cancer  	 NN	O
Bladder  	Bladder  	 NNP	B-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
BCa 	BCa 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
the  	the  	 DT	O
9th  	9th  	 CD	B-NP
most  	most  	 RBS	O
common  	common  	 JJ	O
malignant  	malignant  	 JJ	O
tumor  	tumor  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
13th  	13th  	 JJ	O
leading  	leading  	 JJ	O
cause  	cause  	 NN	O
of  	of  	 IN	O
death  	death  	 NN	O
due  	due  	 JJ	O
to  	to  	 TO	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
surgery  	surgery  	 NN	O
and  	and  	 CC	O
target  	target  	 NN	B-NP
drugs  	drugs  	 NNS	I-NP
bring  	bring  	 VBP	O
new  	new  	 JJ	O
challenges  	challenges  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
traditional  	traditional  	 JJ	O
concept  	concept  	 NN	O
for  	for  	 IN	O
BCa  	BCa  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
chemotherapy  	chemotherapy  	 NN	O
is  	is  	 VBZ	O
still  	still  	 RB	O
the  	the  	 DT	O
final  	final  	 JJ	B-NP
option  	option  	 NN	I-NP
for  	for  	 IN	O
many  	many  	 JJ	O
BCa  	BCa  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
cisplatin-containing  	cisplatin-containing  	 JJ	B-NP
regimen  	regimen  	 NNS	I-NP
the  	the  	 DT	O
most  	most  	 RBS	O
effective  	effective  	 JJ	O
one 	one 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
ubiquitous  	ubiquitous  	 JJ	B-NP
application  	application  	 NN	I-NP
of  	of  	 IN	I-NP
cisplatin-containing  	cisplatin-containing  	 JJ	I-NP
regimen  	regimen  	 NN	I-NP
in  	in  	 IN	O
BCa  	BCa  	 JJ	B-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
cisplatin-resistance 	cisplatin-resistance 	 JJ	B-NP
,  	,  	 ,	O
in  	in  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
cisplatin‑resistant  	cisplatin‑resistant  	 NNP	B-NP
BCa  	BCa  	 NNP	O
manifests  	manifests  	 VBD	O
enhanced  	enhanced  	 VBN	O
malignant  	malignant  	 JJ	O
behavior 	behavior 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
unclear 	unclear 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
present  	present  	 JJ	O
study 	study 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
used  	used  	 VBD	O
BCa  	BCa  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lines  	lines  	 NNS	I-NP
to  	to  	 TO	O
to  	to  	 TO	O
clarify  	clarify  	 VB	O
this  	this  	 DT	O
point 	point 	 NN	O
.  	.  	 .	O
BCa  	BCa  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lines  	lines  	 NNS	I-NP
T24 	T24 	 NNP	I-NP
/ 	/ 	 NNP	O
J82  	J82  	 NNP	B-NP
were  	were  	 VBD	O
pretreated  	pretreated  	 VBN	O
with  	with  	 IN	O
cisplatin  	cisplatin  	 CD	B-NP
> 	> 	 CD	O
3 months  	3 months  	 CD	O
to  	to  	 TO	O
construct  	construct  	 VB	O
stable  	stable  	 JJ	O
cisplatin-resistant  	cisplatin-resistant  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lines  	lines  	 NNS	I-NP
( 	( 	 -LRB-	O
tagged  	tagged  	 FW	O
T24Cis-R  	T24Cis-R  	 FW	O
and  	and  	 CC	O
J82Cis-R 	J82Cis-R 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
which  	which  	 WDT	O
manifested  	manifested  	 VBP	O
as  	as  	 RB	O
enhanced  	enhanced  	 JJ	O
capacity  	capacity  	 NN	O
of  	of  	 IN	O
proliferation  	proliferation  	 NN	B-NP
and  	and  	 CC	O
malignant  	malignant  	 JJ	O
behavior  	behavior  	 NN	O
in vivo  	in vivo  	 NN	O
and  	and  	 CC	O
in vitro 	in vitro 	 NNP	O
,  	,  	 ,	O
accompanied  	accompanied  	 VBN	O
by  	by  	 IN	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
even  	even  	 RB	O
doxorubicin  	doxorubicin  	 JJ	B-NP
resistance 	resistance 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
following  	following  	 JJ	O
mechanism  	mechanism  	 NN	B-NP
dissection  	dissection  	 VBZ	I-NP
revealed  	revealed  	 VBN	O
that  	that  	 IN	O
prolonged  	prolonged  	 JJ	O
treatment  	treatment  	 NN	B-NP
time  	time  	 NN	I-NP
of  	of  	 IN	I-NP
T24 	T24 	 CD	I-NP
/ 	/ 	 CD	O
J82  	J82  	 CD	B-NP
cells  	cells  	 NNS	I-NP
led  	led  	 VBN	O
to  	to  	 TO	O
elevated  	elevated  	 VB	B-NP
expression  	expression  	 NN	I-NP
of  	of  	 IN	I-NP
HIF-1α 	HIF-1α 	 NNP	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
targeted  	targeted  	 VBD	O
the  	the  	 DT	O
increased  	increased  	 JJ	O
expression  	expression  	 NN	O
of  	of  	 IN	O
MDR1  	MDR1  	 CD	B-NP
on  	on  	 IN	O
the  	the  	 DT	O
one  	one  	 CD	O
hand 	hand 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
contributed  	contributed  	 VBD	O
to  	to  	 TO	O
BCa  	BCa  	 JJ	B-NP
cell  	cell  	 NN	I-NP
proliferation 	proliferation 	 NN	I-NP
,  	,  	 ,	O
migration 	migration 	 CD	B-NP
/ 	/ 	 CD	I-NP
invasion  	invasion  	 NN	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
hand 	hand 	 NN	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
IHC  	IHC  	 NNP	B-NP
staining  	staining  	 NN	I-NP
of  	of  	 IN	O
human  	human  	 JJ	O
BCa  	BCa  	 JJ	B-NP
tissue  	tissue  	 NN	I-NP
supported  	supported  	 VBD	O
our  	our  	 PRP$	O
conclusion  	conclusion  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
expression  	expression  	 NN	O
of  	of  	 IN	O
HIF-1α  	HIF-1α  	 NNP	B-NP
and  	and  	 CC	O
MDR1  	MDR1  	 NNP	B-NP
was  	was  	 VBD	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
chemoresistant  	chemoresistant  	 FW	B-NP
tissue  	tissue  	 FW	I-NP
vs.  	vs.  	 FW	O
chemosensitive  	chemosensitive  	 FW	B-NP
tissue 	tissue 	 FW	I-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
results  	results  	 NNS	O
provided  	provided  	 VBD	O
a  	a  	 DT	O
new  	new  	 JJ	O
view  	view  	 NN	O
of  	of  	 IN	O
HIF-1α  	HIF-1α  	 CD	B-NP
in  	in  	 IN	O
chemotherapy 	chemotherapy 	 NN	O
.  	.  	 .	O
